Results 111 to 120 of about 182,500 (270)

Long‐Acting Therapeutics in Pediatric Health: Bridging Innovation and Access

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Children have distinct therapeutic needs arising from age‐dependent physiology, disease epidemiology, formulation requirements, dosing considerations, and safety vulnerabilities. Despite substantial reductions in childhood mortality over the past three decades, nearly 5 million children under five died in 2023, with infectious diseases continuing to ...
Prajith Venkatasubramanian   +5 more
wiley   +1 more source

Exposure–Response Analysis of Enfortumab Vedotin Plus Pembrolizumab as First‐Line Therapy for Locally Advanced or Metastatic Urothelial Cancer

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Enfortumab vedotin is a nectin‐4‐directed antibody–drug conjugate currently approved in combination with pembrolizumab for the first‐line treatment of locally advanced or metastatic urothelial cancer. Here we describe the exposure–response relationship between enfortumab vedotin exposures and efficacy/safety endpoints in patients who received ≥1 dose ...
Vaishali L. Chudasama   +9 more
wiley   +1 more source

Toward Fit‐for‐Purpose Data for Drug Assessment in Non‐small Cell Lung Cancer: A Core Dataset

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Considering the high unmet medical need in people with non‐small cell lung cancer (NSCLC), the drug assessment for targeted therapies often rely on small populations and single‐arm trials, challenging the evaluation by regulatory authorities, health technology assessment bodies (HTAb), and clinicians.
Geeske F. Grit   +6 more
wiley   +1 more source

Long-Term Efficacy of Pembrolizumab and the Clinical Utility of ctDNA in Locally Advanced dMMR/MSI-H Solid Tumors

open access: yesNature Communications
Neoadjuvant immunotherapy can induce pathologic complete response (pCR) in patients with localized deficient mismatch repair (dMMR)/microsatellite instability-high (MSI-H) tumors.
Michael LaPelusa   +14 more
doaj   +1 more source

Pembrolizumab Versus High-Dose Interferon-α2b as Adjuvant Therapy for Pediatric Melanoma: A Retrospective Study

open access: yesDermatology Practical & Conceptual
Introduction: Pembrolizumab is well-tolerated in pediatric patients with advanced tumors, consistent with results in adults. However, information on the safety and efficacy of adjuvant pembrolizumab in children and adolescents with melanoma is lacking.
Yu Du   +14 more
doaj   +1 more source

Exposure‐Response Analyses of Datopotamab Deruxtecan (Dato‐DXd), a TROP2‐Directed Antibody‐Drug Conjugate, in Advanced Non‐small Cell Lung Cancer

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Exposure‐response analyses supported a favorable benefit‐risk profile of Dato‐DXd at 6 mg/kg Q3W in patients with advanced nonsquamous NSCLC. Datopotamab deruxtecan (Dato‐DXd) is a trophoblast cell‐surface antigen‐2 (TROP2)‐directed antibody‐drug conjugate (ADC) that has demonstrated clinical activity in patients with NSCLC who have received prior ...
Ying Hong   +10 more
wiley   +1 more source

Acquired lipodystrophy following use of pembrolizumab

open access: yes
This case report details a 65-year-old female with Hashimoto's hypothyroidism and stage III melanoma who developed acquired generalized lipodystrophy (AGL), a rare immune-mediated adverse event, following pembrolizumab treatment.
Maya Weitzen   +5 more
core   +1 more source

From Enrichment to Insight: Leveraging Preparative cIEF Enrichments and Characterization to Support Data‐Driven Integration Practices for cIEF‐based Analytics

open access: yesELECTROPHORESIS, EarlyView.
Preparative cIEF enrichment enabled isolation of a low‐abundance, poorly resolved basic charge variant identified during routine cIEF analysis. Orthogonal characterization by peptide mapping and SCX‐UV–MS revealed incomplete N‐terminal pyroglutamate formation and Fc methionine oxidation.
Ramya Rao   +14 more
wiley   +1 more source

A Computed Tomography Radiomics Approach for Assessing the T Cell‐Inflamed Gene Expression Profile in Hepatocellular Carcinoma and Its Association With Immunotherapy Response

open access: yesHealth Care Science, EarlyView.
The T cell‐inflamed gene expression profile (GEP) provides a biomarker for immunotherapy response across various cancers. We established a CT‐based radiomics model to predict the T cell‐inflamed GEP and immunotherapy response in hepatocellular carcinoma (HCC).
Mimi Tang   +11 more
wiley   +1 more source

Early Feasibility of Registration of Micro‐PET/CT Scans to Annotated 3D Specimen Models

open access: yesHead &Neck, EarlyView.
ABSTRACT Background Intraoperative 18F‐fluorodeoxyglucose (18F‐FDG) micro‐positron emission tomography/computed tomography (micro‐PET/CT) is an emerging modality for margin assessment. Prior to clinical use, micro‐PET/CT margin distances must be correlated with gold‐standard histopathology.
Joaquin Austerlitz   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy